Website profile

Docwire News

DocWire News delivers the latest health care news, research, and trends in medicine, giving health care professionals access to the curated content most relevant to their fields.

  • 64articles · 30d
  • 18+ hour agolatest article
  • Aug 14, 2026earliest in window
  • 95%with images
  • 267avg words
articles per day
Categories
  • Health & Wellness 64
  • Medical 61
  • Health 59
  • Education 2
  • Finance & Business 2
  • Economy, Business & Finance 1
  • Labour 1
  • Politics 1

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Breast Cancers Today
docwirenews.com > videos > the-evolution-of-the-endocrine-treatment-landscape-for-esr1-mutated-er-her2-negative-metastatic-breast-cancer

Endocrine Therapy for ESR1-Mutated Metastatic Breast Cancer

18+ hour, 45+ min ago   (216+ words) In the first segment of this roundtable series, the panel discusses the current treatment landscape, how it has evolved with new approvals and data, ongoing trials, and what might be on the horizon for patients with ESR1-mutated disease in the…...

Breast Cancers Today
docwirenews.com > videos > choosing-therapy-beyond-the-first-line-in-esr1-mutated-disease-endocrine-sensitivity-disease-tempo-and-patient-centered-factors

Beyond the First-Line for ESR1-Mutated Disease

18+ hour, 45+ min ago   (273+ words) An expert panel moderated by Sara Nunnery, MD, of Tennessee Oncology, convened to discuss how they choose therapy beyond the first-line setting for patients with ESR1-mutated disease. Dr. Nunnery was joined by Nan Chen, MD, of the University of Chicago;…...

Breast Cancers Today
docwirenews.com > videos > biparatopic-her2-targeting-in-action-anbenitamabs-phase-3-breakthrough

Biparatopic HER2 Targeting in Action: Anbenitamab???s Phase 3 Breakthrough

2+ day, 13+ hour ago   (38+ words) Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Docwire News Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Shao ZM, et al. Basch E, et al. 2026 American Society of Clinical Oncology Annual Meeting. Abstract LBA660....

Docwire News
docwirenews.com > videos > playlist > expert-interviews-migraine

Characterizing Menstrual Migraine: Insights From the Global CaMEO-I Study

3+ week, 3+ day ago   (319+ words) Rimegepant May Lead to Better Patient-Reported Outcomes in Episodic Migraine Elismetrep May Provide a New Therapeutic Pathway for Migraine Care In this discussion, Jessica Ailani, MD, a neurologist at MedStar Georgetown University Hospital in Washington, DC, shares insights on managing…...